Predicting Unplanned Hospital Readmissions in Patients With Hematologic Malignancies

Video
Conference|American Society of Hematology Annual Meeting & Exposition (ASH)

This video highlights results of a study that examined predictors for unplanned hospital readmissions in patients with hematologic malignancies.

In this video, Sudipto Mukherjee, MD, MPH, of the Cleveland Clinic in Ohio, discusses results of a study that examined predictors for unplanned hospital readmissions in patients with hematologic malignancies.

Results of the study (abstract 532) were presented at the 2017 American Society of Hematology (ASH) Annual Meeting and Exposition, held December 9–12 in Atlanta.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Greater direct access to academic oncologists may help address challenges associated with a lack of CAR T education in the community setting.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
A retrospective study sought to assess CRS and ICANS onset and duration, as well as non-relapse mortality causes in patients infused with CAR T-cell therapies.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Related Content
Zanubrutinib tablets were found to have the same efficacy and safety as capsules based on 2 single-dose, open-label randomized phase 1 studies.

FDA Approves Zanubrutinib Tablets in Multiple Hematologic Indications

Roman Fabbricatore
June 12th 2025
Article

Zanubrutinib tablets were found to have the same efficacy and safety as capsules based on 2 single-dose, open-label randomized phase 1 studies.

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

Low Rates of Chronic Graft-Versus-Host Disease With Ruxolitinib Maintenance Following Allogeneic HCT

Low Rates of Chronic Graft-Versus-Host Disease With Ruxolitinib Maintenance Following Allogeneic HCT

American Society for Transplantation and Cellular Therapy
June 2nd 2025
Article

Researchers conducted a prospective, multicenter phase II clinical trial demonstrating that prolonged administration of ruxolitinib after allogeneic HCT is associated with notably low rates of cGVHD.

Therapies like betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD
May 5th 2025
Podcast

Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Findings support the established safety profile of lisocabtagene maraleucel across hematologic oncology indications.

Data Show Low Severity AEs With Liso-Cel Across Blood Cancer Settings

Russ Conroy
June 1st 2025
Article

Findings support the established safety profile of lisocabtagene maraleucel across hematologic oncology indications.

FDA Gives Fast Track Designation to Givinostat for Polycythemia Vera

FDA Gives Fast Track Designation to Givinostat for Polycythemia Vera

Tim Cortese
May 6th 2025
Article

The phase 3 GIV-IN PV trial is evaluating the efficacy and safety of givinostat vs hydroxyurea in patients with polycythemia vera.